- Metastasis-directed therapy (MDT) is associated with improved OS of patients with head and neck squamous cell carcinoma (HNSCC) with limited metastatic disease burden.
Why this matters
- This study adds to mounting evidence for a beneficial role of local therapy strategies in patients with limited metastatic burden.
- 5-year OS was 9% in the entire cohort (35% in patients with a single metastasis, 4% in patients with multiple metastases).
- MDT was associated with improved OS (HR, 0.36; P=.006) in multivariate analysis.
- Oral cavity primary (HR, 2.22; P=.015) and sinonasal primary (HR, 4.88; P=.037) were associated with reduced OS in multivariate analysis.
- Estimated median metastasis-free survival and 5-year OS after MDT were 26.4 months and 31%, respectively.
- 186 patients with HNSCC and metastatic disease, 16.1% who underwent MDT (14% surgery, 1.6% radiation therapy, 0.5% radiofrequency ablation), were analyzed for outcomes and associated factors.
- Funding: NIH/National Cancer Institute.
- Retrospective study with patient and treatment heterogeneity.